Pertuzumab (Perjeta®) injection was approved to be used in combination with trastuzumab and docetaxel.  A black box warning warns that fetal exposure may cause birth defects or death and women should be advised to use contraception during treatment and for six months after the last dose. What situations warrant a black box warning on a drug’s label?

 

http://www.ashp.org/menu/News/PharmacyNews/NewsArticle.aspx?Source=News&Type=Rss&Id=3730

Advertisements